Learning Objectives
Upon completion of this activity, participants should be able to:
- Analyze the role of mismatch repair deficiency in determining therapy for patient with stage II or III colorectal cancer (CRC)
- Interpret the role of bevacizumab as adjuvant therapy in patients with stage II or III CRC
- Evaluate the relationship between KRAS status and anti-EGFR therapy
- Appraise the use of prophylactic skin treatment in patients receiving anti-EGFR therapy
- Assess the use of intravenous calcium and magnesium to prevent oxaliplatin-related neurotoxicity
CCO Video Module contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.